{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:50:39Z","timestamp":1789098639342,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ajt.2023.05.032","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T16:08:43Z","timestamp":1685635723000},"page":"1603-1611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3253-1744","authenticated-orcid":false,"given":"Filip","family":"Cvetkovski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6715-0798","authenticated-orcid":false,"given":"Ronia","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-244X","authenticated-orcid":false,"given":"Felix","family":"Sellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-7348","authenticated-orcid":false,"given":"Erik","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-0939","authenticated-orcid":false,"given":"David","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ajt.2023.05.032_bib1","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ajt.2023.05.032_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2023.05.032_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajt.2023.05.032_bib4","doi-asserted-by":"crossref","first-page":"942665","DOI":"10.3389\/fmed.2022.942665","article-title":"Belatacept in kidney transplantation: What are the true benefits? A systematic review","volume":"9","author":"Lombardi","year":"2022","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.ajt.2023.05.032_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14531","article-title":"Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States","volume":"36","author":"Karadkhele","year":"2022","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2023.05.032_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-6143.2010.03317.x","article-title":"Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression","volume":"11","author":"Lo","year":"2011","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2023.05.032_bib7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nm.1993","article-title":"Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates","volume":"15","author":"Weaver","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ajt.2023.05.032_bib8","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3389\/fimmu.2020.01090","article-title":"CD2 immunobiology","volume":"11","author":"Binder","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ajt.2023.05.032_bib9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ajt.15533","article-title":"Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro","volume":"20","author":"Podest\u00e0","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2023.05.032_bib10","doi-asserted-by":"crossref","first-page":"592553","DOI":"10.3389\/fimmu.2020.592553","article-title":"Siplizumab, an anti-CD2 monoclonal antibody, induces a unique set of immune modulatory effects compared to alemtuzumab and rabbit anti-thymocyte globulin in vitro","volume":"11","author":"Binder","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajt.2023.05.032_bib11","doi-asserted-by":"crossref","first-page":"599526","DOI":"10.3389\/fimmu.2021.599526","article-title":"Siplizumab induces NK cell fratricide through antibody-dependent cell-mediated cytotoxicity","volume":"12","author":"Binder","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ajt.2023.05.032_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12839","article-title":"Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody","volume":"91","author":"Sellberg","year":"2020","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.ajt.2023.05.032_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/tri.13524","article-title":"Safety and pharmacodynamics of anti-CD2 monoclonal antibody treatment in cynomolgus macaques \u2013 an experimental study","volume":"33","author":"Berglund","year":"2020","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.ajt.2023.05.032_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-mismatched renal\u00a0transplantation without maintenance immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N\u00a0Engl\u00a0J Med"},{"issue":"7","key":"10.1016\/j.ajt.2023.05.032_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/ajt.12731","article-title":"Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression","volume":"14","author":"Kawai","year":"2014","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2023.05.032_bib16","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/ajt.14251","article-title":"Origin of enriched regulatory t cells in patients receiving combined kidney-bone marrow transplantation to induce transplantation tolerance","volume":"17","author":"Sprangers","year":"2017","journal-title":"Am J Transplant"},{"issue":"22","key":"10.1016\/j.ajt.2023.05.032_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124086","article-title":"Early expansion of donor-specific Tregs in tolerant kidney transplant recipients","volume":"3","author":"Savage","year":"2018","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.ajt.2023.05.032_bib18","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2215\/CJN.13100820","article-title":"Belatacept for simultaneous calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance: two-year results of a prospective, randomized multicenter trial","volume":"16","author":"Kaufman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ajt.2023.05.032_bib19","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/ajt.14350","article-title":"Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients","volume":"17","author":"Cortes-Cerisuelo","year":"2017","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2023.05.032_bib20","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.14349","article-title":"Belatacept-resistant rejection is associated with CD28 + memory CD8 T cells","volume":"17","author":"Mathews","year":"2017","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2023.05.032_bib21","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ajt.13613","article-title":"CD57 + CD4 T cells underlie belatacept-resistant allograft rejection","volume":"16","author":"Espinosa","year":"2016","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.ajt.2023.05.032_bib22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.4049\/jimmunol.152.6.2753","article-title":"Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure\/function analysis in vitro and in human CD2 transgenic mice","volume":"152","author":"Majeau","year":"1994","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.ajt.2023.05.032_bib23","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.4049\/jimmunol.178.11.7442","article-title":"Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients","volume":"178","author":"Haider","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.ajt.2023.05.032_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/TP.0b013e31829f1607","article-title":"inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans","volume":"96","author":"Levitsky","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.ajt.2023.05.032_bib25","doi-asserted-by":"crossref","first-page":"600000","DOI":"10.3389\/fimmu.2020.600000","article-title":"CD86 is a selective CD28 ligand supporting FoxP3+ regulatory T cell homeostasis in the presence of high levels of CTLA-4","volume":"11","author":"Halliday","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajt.2023.05.032_bib26","doi-asserted-by":"crossref","first-page":"969633","DOI":"10.3389\/fimmu.2022.969633","article-title":"Costimulation blockade and Tregs in solid organ transplantation","volume":"13","author":"Muckenhuber","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ajt.2023.05.032_bib27","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1600-6143.2008.02377.x","article-title":"The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation","volume":"8","author":"Bluestone","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2023.05.032_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fimmu.2017.00219","article-title":"Methylation of FOXP3 TSDR underlies the impaired suppressive function of Tregs from long-term belatacept-treated kidney transplant patients","volume":"8","author":"Alvarez Salazar","year":"2017","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.ajt.2023.05.032_bib29","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.4049\/jimmunol.1601538","article-title":"First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28","volume":"197","author":"Poirier","year":"2016","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"10.1016\/j.ajt.2023.05.032_bib30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.molimm.2004.05.004","article-title":"Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies","volume":"41","author":"Damschroder","year":"2004","journal-title":"Mol Immunol"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613523005208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613523005208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:40:18Z","timestamp":1761630018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613523005208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1600613523005208"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2023.05.032","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2023.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}